Recombinant Mouse B-lymphocyte antigen CD19 (Cd19)

What is mouse CD19 and what is its biological significance?

Mouse CD19 is a transmembrane glycoprotein that functions as a critical coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. It plays an essential role in B cell activation by decreasing the threshold for activation of downstream signaling pathways and enhancing B-cell responses to antigens. Mechanistically, CD19 activates pathways leading to phosphatidylinositol 3-kinase activation and mobilization of intracellular Ca²⁺ stores, which are crucial for proper B cell function and development . CD19 is required for normal B cell differentiation and proliferation in response to antigen challenges, particularly for the production of high-affinity antibodies. While CD19 is not essential for early B cell differentiation in the bone marrow, it is required for normal differentiation of B-1 cells and maintaining appropriate levels of serum immunoglobulins .

What are the structural properties of recombinant mouse CD19 protein?

Recombinant mouse CD19 protein is typically produced with a polyhistidine tag (His-Tag) at the C-terminus to facilitate purification and detection. The protein has a calculated molecular weight of approximately 31.6 kDa, but it migrates as a 45-55 kDa protein on SDS-PAGE under reducing conditions due to glycosylation . High-quality recombinant mouse CD19 proteins are designed to maintain optimal monomer rates, which is crucial for experimental reproducibility . They are generally lyophilized from filtered solutions in PBS (pH 7.4) with trehalose as a protectant to maintain stability during storage and shipping . The glycosylation pattern of recombinant mouse CD19 is an important structural feature that affects both its function and stability in experimental applications.

What experimental methods can be used to validate recombinant mouse CD19 protein activity?

Several complementary techniques are employed to validate recombinant mouse CD19 protein activity:

• SDS-PAGE analysis: Confirms protein purity (typically >90%) and proper molecular weight (45-55 kDa under reducing conditions due to glycosylation) .

• ELISA binding assays: Used to verify functional activity by measuring binding to anti-CD19 antibodies. For example, immobilized Rat/IgG2a Kappa Anti-CD19 Antibody at 1 μg/mL can bind Mouse CD19-His Tag with a linear range of 0.02-0.313 μg/mL .

• Surface Plasmon Resonance (SPR): Measures binding kinetics and affinity constants. Protein G-captured Rat/IgG2a Kappa Anti-CD19 Antibody can bind Mouse CD19-His Tag with an affinity constant of 5.76 nM as determined by SPR assay using Biacore 8K systems .

• Flow cytometry: Used to assess binding to CD19-expressing cells or to detect CAR expression on engineered T cells. FITC-conjugated CD19 can be particularly useful for detecting CD19-specific CAR expression via FACS .

How should recombinant mouse CD19 protein be stored for optimal stability?

For optimal stability and activity retention, recombinant mouse CD19 protein should be maintained in a lyophilized state at -20°C or lower for long-term storage . Researchers should strictly avoid repeated freeze-thaw cycles as these significantly compromise protein integrity and activity. Upon reconstitution, it is strongly recommended to follow the specific protocol provided in the Certificate of Analysis (CoA) that accompanies the protein . Typically, reconstitution involves using filtered PBS or a similar buffer, depending on downstream applications. For working solutions, storage at 4°C is generally acceptable for short periods (1-2 weeks), but aliquoting and re-freezing at -80°C is recommended for longer-term storage of reconstituted protein to minimize degradation.

How is recombinant mouse CD19 utilized in CAR-T cell therapy development?

Recombinant mouse CD19 is instrumental in developing and validating chimeric antigen receptor (CAR) T cell therapies for preclinical models. CD19-targeted CAR T cells have shown remarkable efficacy in murine models of B cell malignancies and autoimmune conditions. In lupus models, CD8+ T cells expressing CD19-targeted CARs persistently depleted CD19+ B cells, eliminated autoantibody production, reversed disease manifestations in target organs, and significantly extended lifespan in (NZB × NZW) F1 and MRL/fas/fas mouse models .

Methodologically, researchers use recombinant mouse CD19 to:

• Screen CAR constructs: Testing binding affinity and specificity of novel CAR designs before in vivo studies

• Validate CAR expression: Using flow cytometry with fluorescently-labeled CD19 proteins to confirm CAR expression on transduced T cells

• Select optimal T cell subsets: CAR T cells derived from CD44+CD62L+ T cell subsets demonstrated enhanced persistence, remaining active for up to one year in vivo in lupus models

• Assess CAR-T functionality: Measuring cytokine production, proliferation, and cytotoxicity upon exposure to recombinant CD19

The effectiveness of CD19-CAR T cell therapy in these models suggests its potential translation to clinical trials for human lupus and other autoimmune diseases characterized by pathogenic B cell activity .

What are the methods for generating CD19-expressing transgenic mouse models?

Several approaches have been developed to create transgenic mouse models for studying CD19 function and CD19-expressing cells:

• CD19-Cre Knock-in Strategy: Traditional CD19-Cre mice have Cre recombinase inserted into the CD19 locus, resulting in disruption of one CD19 allele, which can lead to suboptimal recombination efficiency in early B cell development stages .

• CD19-iCre (improved Cre) Model: This improved model incorporates the T2A-iCre sequence inserted before the stop codon of the Cd19 gene, preserving CD19 expression while enabling Cre activity. When crossed with Rosa26-EYFP reporter mice, CD19-iCre mice demonstrated more effective recombination in early B cell developmental stages compared to traditional CD19-Cre mice .

• Bhlhe41 dTomato-Cre Fate Mapping: This transgenic model allows lineage tracing of B-1 cells. Using this system, researchers detected CD19 expression patterns across different B cell developmental stages. Less than 1% of dTomato+EYFP+ cells were found in Pro-B and Pre-B (CD19+IgD-IgM-) cells, immature B (CD19+IgD-IgM+), and circulating B cells (CD19+IgD+IgM+) from bone marrow, indicating selective Bhlhe41 expression patterns .

• CD19-CreERT2 System: This inducible system incorporates the tamoxifen-responsive CreERT2 recombinase into the CD19 locus, allowing for temporal control of Cre-mediated recombination specifically in B cells .

These genetic tools are essential for studying B cell development, function, and for creating B cell-specific gene knockouts with high specificity and efficiency.

How does CD19 signaling integrate with other pathways in B cell survival?

CD19 plays a pivotal role in B cell survival through its integration with multiple signaling pathways. Studies using Syk-deficient B cells have demonstrated that both BAFF receptor and CD19/PI3K signaling are required for long-term B cell survival in vivo . This finding highlights the cooperative nature of these pathways in maintaining B cell homeostasis.

Mechanistically, CD19 functions as a critical component of the B cell co-receptor complex, which amplifies BCR signaling through several pathways:

• PI3K Pathway Activation: CD19 directly recruits PI3K through its cytoplasmic tail, leading to Akt activation and promotion of cell survival signals.

• Calcium Mobilization: CD19 enhances intracellular Ca2+ mobilization following BCR engagement, which activates multiple downstream effectors including calcineurin and NFAT transcription factors .

• Integration with BAFF-R Signaling: While CD19 primarily amplifies antigen-specific signals, BAFF-R provides tonic survival signals. The convergence of these pathways on common downstream effectors, particularly in the PI3K/Akt axis, creates a robust survival network .

• Cooperation with CD22 and CD20: CD19's connection with proteins like CD22 (a negative regulator) and CD20 is particularly important in pathological contexts, making these interactions valuable targets for therapeutic intervention .

This integrated signaling network provides multiple intervention points for targeting B cell malignancies and autoimmune disorders where aberrant B cell survival contributes to disease pathology.

What are the critical quality attributes of recombinant mouse CD19 for immunotherapy research?

For immunotherapy research applications, recombinant mouse CD19 proteins must meet several critical quality attributes to ensure experimental reliability and translational relevance:

Researchers should carefully validate these attributes when selecting recombinant mouse CD19 for immunotherapy studies. For CAR-T cell development specifically, the protein should demonstrate binding to the CAR construct with affinity similar to that observed with native CD19 expressed on B cells. Additionally, for flow cytometry applications, fluorophore-conjugated CD19 should maintain both fluorescence stability and antigen recognition properties .

How do mouse models of CD19-targeted therapies translate to human applications?

The translation from mouse models of CD19-targeted therapies to human applications involves several important considerations:

• Structural Homology: While mouse and human CD19 share significant homology, they differ in certain epitopes. This affects antibody cross-reactivity and necessitates species-specific development of therapeutic antibodies. CAR constructs developed against mouse CD19 typically do not recognize human CD19 and vice versa .

• Disease Model Relevance: CD19-targeted CAR T cells have shown remarkable efficacy in murine models of lupus, eliminating autoantibody production and extending lifespans. These findings provide strong rationale for exploring similar approaches in human lupus and other autoimmune diseases characterized by pathogenic B cells .

• T Cell Persistence: In mouse models, CD19-CAR T cells remained active for up to one year in vivo and were enriched in the CD44+CD62L+ T cell subset, suggesting that targeting specific T cell subsets for CAR engineering might enhance therapeutic durability in humans .

• B Cell Depletion Consequences: Complete B cell depletion in mice may have different immunological consequences compared to humans, particularly regarding infection susceptibility and immune reconstitution kinetics.

• Species-Specific Signaling Networks: Differences in B cell signaling networks between mice and humans may affect the response to CD19-targeted therapies and development of resistance mechanisms.

For improved translational research, using humanized mouse models and testing therapies against both mouse and human CD19 proteins in parallel can provide more predictive preclinical data for human clinical applications.

How can researchers overcome challenges in working with glycosylated recombinant mouse CD19?

Working with glycosylated recombinant mouse CD19 presents several challenges due to its complex post-translational modifications. These challenges can be addressed through specific methodological approaches:

• Heterogeneous Glycosylation Patterns: Mouse CD19 typically migrates as 45-55 kDa on SDS-PAGE due to glycosylation, despite having a calculated MW of 31.6 kDa . To address this heterogeneity:

  • Use deglycosylation enzymes (PNGase F, Endo H) to remove N-linked glycans for applications requiring homogeneous protein

  • When analyzing by western blot, include positive controls with known glycosylation patterns

  • Consider using multiple antibodies targeting different epitopes to ensure detection regardless of glycosylation state

• Stability Concerns: Glycoproteins can be less stable than non-glycosylated proteins. To maintain stability:

  • Store lyophilized protein at -20°C or lower

  • Include stabilizing agents like trehalose in formulation buffers

  • Strictly avoid repeated freeze-thaw cycles

  • Aliquot reconstituted protein to minimize freeze-thaw events

• Binding Interference: Glycans may interfere with antibody binding in certain applications. To overcome this:

  • Validate antibodies specifically with glycosylated recombinant CD19

  • Consider the impact of glycosylation when interpreting binding kinetics data

  • For epitope mapping studies, compare results between native and deglycosylated forms

• Expression System Selection: Different expression systems produce varying glycosylation patterns. For most similar-to-native glycosylation:

  • Prefer mammalian expression systems (CHO, HEK293) over bacterial or insect cell systems

  • Validate glycosylation patterns by mass spectrometry when glycan structure is critical for the application

What controls should be included when using recombinant mouse CD19 in experimental setups?

Robust experimental design with appropriate controls is essential when working with recombinant mouse CD19:

• Specificity Controls:

  • Include an isotype-matched control antibody in binding assays

  • Use CD19-knockout cells as negative controls in cellular assays

  • For CAR-T cell assays, include T cells expressing non-targeting CARs

• Functional Validation Controls:

  • Positive control: Commercial anti-CD19 antibody with known binding characteristics

  • Binding comparisons to recombinant human CD19 when testing cross-reactivity

  • Include native CD19 from mouse B cell lysates when comparing to recombinant protein

• Technical Controls:

  • Fresh vs. stored protein comparisons to assess stability

  • Multiple protein concentrations to establish dose-response relationships

  • Buffer-only controls to detect non-specific effects

• Internal Standards:

  • Include a reference lot of well-characterized recombinant CD19

  • For quantitative assays, establish standard curves using validated reference material

  • When using CD19 for cell sorting or detection, include fluorescence-minus-one (FMO) controls

• Species Specificity Controls:

  • When testing antibodies or CARs designed for mouse CD19, confirm specificity by testing against human CD19

  • For translational research, include parallel testing with both mouse and human proteins

Including these controls ensures experimental rigor and facilitates troubleshooting if unexpected results occur.

How can researchers effectively use CD19 transgenic mouse models to study B cell development?

Transgenic mouse models targeting CD19 provide powerful tools for studying B cell development, but require careful methodological considerations:

• Selection of Appropriate CD19 Transgenic Model:

  • Traditional CD19-Cre mice show relatively low recombination efficiency in early B cell stages

  • CD19-iCre models offer improved recombination in early developmental stages while preserving CD19 expression

  • Inducible CD19-CreERT2 systems provide temporal control of recombination

  • Consider using homozygous Cre mice for higher recombination efficiency

• Monitoring Developmental Stages:

  • Use flow cytometry with stage-specific markers to track B cell development:

    • Pro/Pre-B cells: CD19+IgD-IgM-

    • Immature B cells: CD19+IgD-IgM+

    • Circulating B cells: CD19+IgD+IgM+

    • Follicular B cells: CD19+IgD+IgMlo/-

    • Marginal zone B cells: CD19+IgDlo/-IgM+

• Lineage Tracing Strategies:

  • Cross CD19-Cre mice with reporter lines (Rosa26-EYFP or Rosa26-tdTomato)

  • Use reporter expression to track cell fate during development

  • Flow cytometry and immunohistochemistry can be used to assess reporter expression

• Functional Assessment:

  • Conduct adoptive transfer experiments to assess functionality of defined B cell populations

  • Measure antibody production in response to T-dependent and T-independent antigens

  • Assess calcium flux and signaling pathway activation in response to stimuli

• Integrating with Gene Targeting:

  • When studying specific gene function, cross CD19-Cre mice with mice carrying floxed alleles

  • Validate recombination efficiency by PCR of genomic DNA from sorted B cell populations

  • Western blotting can confirm protein deletion in targeted cells

These approaches enable comprehensive analysis of B cell development and function in both normal and pathological conditions, with applications in understanding autoimmunity, B cell malignancies, and immune response regulation.

What emerging approaches are advancing CD19-targeted therapies beyond current applications?

Several innovative approaches are expanding the frontier of CD19-targeted therapies:

• Dual-Targeting CAR Constructs: To address antigen escape in CD19-targeted therapies, researchers are developing CAR-T cells that simultaneously target CD19 and other B-cell antigens. This approach may enhance efficacy and reduce resistance in both cancer and autoimmune disease models.

• Controllable CAR Systems: Development of inducible or switchable CAR systems that can be modulated post-infusion allows for better safety control and potentially reduced toxicity when targeting CD19 in vivo.

• B Cell-Selective Depletion: Rather than depleting all CD19+ cells, engineering CARs that recognize specific CD19 conformations or co-receptors unique to pathogenic B cell subsets could enable more selective targeting.

• Novel Mouse Models: Advanced CD19-iCre and CD19-CreERT2 mouse models are enabling more precise studies of B cell biology and CD19-targeted therapies . These models preserve CD19 expression while allowing efficient gene manipulation in B cells.

• Integration with Checkpoint Inhibition: Combining CD19-targeted approaches with immune checkpoint modulation may enhance effectiveness, particularly in settings where immune suppression limits CAR-T cell function.

• Non-Cellular CD19-Directed Therapies: Beyond CAR-T cells, novel modalities including CD19-targeted protein degraders, RNA therapeutics, and small molecule modulators of CD19 signaling represent emerging approaches with potential advantages in manufacturability and safety.

These approaches represent the leading edge of CD19-targeted therapeutic development, with significant potential to address current limitations in specificity, durability, and safety.

How might understanding CD19 biology contribute to new therapeutic paradigms?

Deeper understanding of CD19 biology is catalyzing new therapeutic approaches:

• Structural Analysis for Rational Design: Detailed structural characterization of mouse and human CD19 enables rational design of therapeutic antibodies and CARs with optimal binding characteristics and reduced immunogenicity.

• Signaling Network Manipulation: Understanding how CD19 intersects with other signaling pathways, particularly BAFF-R signaling , creates opportunities for combination therapies that synergistically modulate B cell survival, potentially with lower toxicity than complete B cell depletion.

• Developmental Stage-Specific Targeting: CD19 expression varies across B cell developmental stages, potentially allowing for selective targeting of pathogenic B cell subsets while sparing beneficial populations. This approach could revolutionize treatment of autoimmune diseases where certain B cell subsets drive pathology.

• Biomarker Development: Understanding CD19 shedding, internalization, and recycling dynamics could enable development of biomarkers to predict and monitor response to CD19-targeted therapies.

• Novel Model Systems: Advanced mouse models like CD19-iCre and Bhlhe41 dTomato-Cre facilitate more precise studies of CD19 biology in normal and disease states, potentially identifying new therapeutic targets and approaches.

• Translational Optimization: Comparative studies of mouse and human CD19 biology enhance translational relevance of preclinical findings, potentially improving success rates in clinical development.

These advances collectively suggest a future where therapies targeting CD19 and related pathways achieve greater precision, efficacy, and safety through deeper biological understanding rather than empirical development.